{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:27:09Z","timestamp":1791289629819,"version":"4.3.0"},"update-to":[{"DOI":"10.12688\/gatesopenres.15569.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000}}],"reference-count":44,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["220991\/Z\/20\/Zand203077\/Z\/16\/Z"],"award-info":[{"award-number":["220991\/Z\/20\/Zand203077\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"crossref","award":["INV-039626"],"award-info":[{"award-number":["INV-039626"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"name":"US CDC through a Cooperative Agreement to Washington State University Global Health Kenya","award":["6U01GH002143"],"award-info":[{"award-number":["6U01GH002143"]}]}],"content-domain":{"domain":["gatesopenresearch.org"],"crossmark-restriction":false},"short-container-title":["Gates Open Res"],"abstract":"<ns3:p>The Kenya Multi Site Serosurveillance (KEMIS) collaboration set out to implement an integrated, nationally representative, population-based program of serological surveillance for past infection for a number of important infectious diseases in Kenya. The project started in December 2021 and built on a portfolio of SARS-CoV-2 research conducted in 2020 and 2021. In this profile paper, we describe the background of the KEMIS collaboration, its aim and objectives, the Health and Demographic Surveillance System sites that were involved in data collection, and the key activities undertaken. We also explain how we established governance and management of the KEMIS collaboration, and reflect on opportunities, challenges, lessons learned, and future directions.<\/ns3:p>","DOI":"10.12688\/gatesopenres.15569.2","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T10:30:14Z","timestamp":1740652214000},"page":"60","update-policy":"https:\/\/doi.org\/10.12688\/gatesopenres.crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Profile: The Kenya Multi-Site Serosurveillance (KEMIS) collaboration"],"prefix":"10.12688","volume":"8","author":[{"given":"E. Wangeci","family":"Kagucia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7382-8675","authenticated-orcid":false,"given":"Shirine","family":"Voller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdhalah K.","family":"Ziraba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godfrey","family":"Bigogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9419-7155","authenticated-orcid":false,"given":"Patrick K.","family":"Munywoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimani","family":"Makobu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. James","family":"Nokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Nyagwange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameline","family":"Orlendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Akech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antipa","family":"Sigilai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton","family":"Onyango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonventure","family":"Juma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Herman-Roloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peninah","family":"Munyua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5776-1750","authenticated-orcid":false,"given":"Caroline","family":"Apondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Lidechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Audi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Ouma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Aol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Misore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Nasimiyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1634-0531","authenticated-orcid":false,"given":"Dickens","family":"Onyango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrence","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadondi","family":"Kasera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Jalang'o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Kingwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ifedayo","family":"Adetifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony O.","family":"Etyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Warimwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8760-1279","authenticated-orcid":false,"given":"Ambrose","family":"Agweyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Anthony G.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"79-82","DOI":"10.1126\/science.abe1916","article-title":"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors.","volume":"371","author":"S Uyoga","year":"2021","journal-title":"Science."},{"key":"ref-2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24062-3","article-title":"Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.","volume":"12","author":"I Adetifa","year":"2021","journal-title":"Nat Commun."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"288-293","DOI":"10.1093\/cid\/ciab346","article-title":"Seroprevalence of antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 among healthcare workers in Kenya.","volume":"74","author":"A Etyang","year":"2022","journal-title":"Clin Infect Dis."},{"key":"ref-4","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab314","article-title":"Anti-Severe Acute Respiratory Syndrome Coronavirus 2 immunoglobulin G antibody seroprevalence among truck drivers and assistants in Kenya.","volume":"8","author":"E Kagucia","year":"2021","journal-title":"Open Forum Infect Dis."},{"key":"ref-5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0000883","article-title":"SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021.","volume":"2","author":"A Etyang","year":"2022","journal-title":"PLOS Glob Public Health."},{"key":"ref-6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265478","article-title":"Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21.","volume":"17","author":"R Lucinde","year":"2022","journal-title":"PLoS One."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"853","DOI":"10.12688\/f1000research.72914.2","article-title":"Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi, Kenya, December 2020 [version 2; peer review: 2 approved].","volume":"10","author":"P Munywoki","year":"2021","journal-title":"F1000Res."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.12688\/gatesopenres.14684.2","article-title":"Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021 [version 2; peer review: 2 approved, 1 approved with reservations].","volume":"7","author":"P Munywoki","year":"2023","journal-title":"Gates Open Res."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"25-34","DOI":"10.1016\/j.ijid.2021.08.062","article-title":"High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya.","volume":"112","author":"I Ngere","year":"2021","journal-title":"Int J Infect Dis."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"650-7","DOI":"10.1093\/ije\/dys062","article-title":"Profile: the Kilifi Health and Demographic Surveillance System (KHDSS).","volume":"41","author":"J Scott","year":"2012","journal-title":"Int J Epidemiol."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"462-71","DOI":"10.1093\/ije\/dyu251","article-title":"Health & demographic surveillance system profile: the Nairobi Urban Health and Demographic Surveillance System (NUHDSS).","volume":"44","author":"D Beguy","year":"2015","journal-title":"Int J Epidemiol."},{"key":"ref-12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016085","article-title":"The burden of common infectious disease syndromes at the clinic and household level from population-based surveillance in rural and urban Kenya.","volume":"6","author":"D Feikin","year":"2011","journal-title":"PLoS One."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"977-87","DOI":"10.1093\/ije\/dys108","article-title":"Profile: the KEMRI\/CDC health and demographic surveillance system--western Kenya.","volume":"41","author":"F Odhiambo","year":"2012","journal-title":"Int J Epidemiol."},{"key":"ref-14","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-0827-x","article-title":"Severe acute respiratory infection in children in a densely populated urban slum in Kenya, 2007-2011.","volume":"15","author":"R Breiman","year":"2015","journal-title":"BMC Infect Dis."},{"key":"ref-15","article-title":"2019 Kenya population and housing census: population by county and sub-county.","year":"2019"},{"key":"ref-16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28266-4","article-title":"Modeling and mapping the burden of disease in Kenya.","volume":"8","author":"M Frings","year":"2018","journal-title":"Sci Rep."},{"key":"ref-17","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13173","article-title":"SARS-CoV-2 seroprevalence and implications for population immunity: evidence from two health and demographic surveillance system sites in Kenya, February-December 2022.","volume":"17","author":"E Kagucia","year":"2023","journal-title":"Influenza Other Respir Viruses."},{"key":"ref-18","article-title":"First WHO International Standard for anti-SARS-CoV-2 immunoglobulin (human); NIBSC code: 20\/136."},{"key":"ref-19","article-title":"SCoV-2 Detect\u2122 IgG ELISA."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"356-358","DOI":"10.1016\/S0140-6736(23)00964-9","article-title":"Learning from serosurveillance for SARS-CoV-2 to inform pandemic preparedness and response.","volume":"402","year":"2023","journal-title":"Lancet."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"1188-94","DOI":"10.3201\/eid2407.171928","article-title":"Integrated serologic surveillance of population immunity and disease transmission.","volume":"24","author":"B Arnold","year":"2018","journal-title":"Emerg Infect Dis."},{"key":"ref-22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010657","article-title":"Building an integrated serosurveillance platform to inform public health interventions: insights from an experts' meeting on serum biomarkers.","volume":"16","author":"K Wiens","year":"2022","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"728-30","DOI":"10.1016\/S0140-6736(16)30164-7","article-title":"Use of serological surveys to generate key insights into the changing global landscape of infectious disease.","volume":"388","author":"C Metcalf","year":"2016","journal-title":"Lancet."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"396-400","DOI":"10.1128\/CVI.05537-11","article-title":"Development of a bead-based multiplex immunoassay for simultaneous quantitative detection of IgG serum antibodies against measles, mumps, rubella, and varicella-zoster virus.","volume":"19","author":"G Smits","year":"2012","journal-title":"Clin Vaccine Immunol."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"79-89","DOI":"10.1016\/j.jim.2008.02.018","article-title":"Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus.","volume":"335","author":"P van Gageldonk","year":"2008","journal-title":"J Immunol Methods."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"3287-96","DOI":"10.1016\/s0264-410x(00)00125-0","article-title":"European sero-epidemiology network: standardisation of the results of diphtheria antitoxin assays.","volume":"18","author":"C von Hunolstein","year":"2000","journal-title":"Vaccine."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"175-8","DOI":"10.1056\/NEJM196401232700404","article-title":"The prophylactic dose of homologous tetanus antitoxin.","volume":"270","author":"J McComb","year":"1964","journal-title":"N Engl J Med."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"1036-42","DOI":"10.1093\/infdis\/162.5.1036","article-title":"Measles antibody: reevaluation of protective titers.","volume":"162","author":"R Chen","year":"1990","journal-title":"J Infect Dis."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"2139-44","DOI":"10.1128\/jcm.30.8.2139-2144.1992","article-title":"Comparison of a neutralization enzyme immunoassay and an enzyme-linked immunosorbent assay for evaluation of immune status of children vaccinated for mumps.","volume":"30","author":"T Harmsen","year":"1992","journal-title":"J Clin Microbiol."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"170-4","DOI":"10.1093\/ajcp\/106.2.170","article-title":"Rubella immunity. Defining the level of protective antibody.","volume":"106","author":"L Skendzel","year":"1996","journal-title":"Am J Clin Pathol."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"10-6","DOI":"10.1093\/infdis\/jit143","article-title":"Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage.","volume":"208","author":"S Waaijenborg","year":"2013","journal-title":"J Infect Dis."},{"key":"ref-32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014183","article-title":"Seroprevalence of pertussis in the Netherlands: evidence for increased circulation of Bordetella pertussis.","volume":"5","author":"S de Greeff","year":"2010","journal-title":"PLoS One."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"333-8","DOI":"10.1097\/INF.0000000000000576","article-title":"Seroprevalence of pertussis in the Gambia: evidence for continued circulation of Bordetella pertussis despite high vaccination rates.","volume":"34","author":"S Scott","year":"2015","journal-title":"Pediatr Infect Dis J."},{"key":"ref-34","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101669","article-title":"Naturally acquired Rift Valley Fever virus neutralizing antibodies predominantly target the Gn glycoprotein.","volume":"23","author":"D Wright","year":"2020","journal-title":"iScience."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.12688\/wellcomeopenres.16748.3","article-title":"Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data [version 3; peer review: 2 approved, 1 approved with reservations].","volume":"6","author":"J Ojal","year":"2022","journal-title":"Wellcome Open Res."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"989-94","DOI":"10.1126\/science.abk0414","article-title":"COVID-19 transmission dynamics underlying epidemic waves in Kenya.","volume":"374","author":"S Brand","year":"2021","journal-title":"Science."},{"key":"ref-37","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2022-009430","article-title":"Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya.","volume":"7","author":"S Orangi","year":"2022","journal-title":"BMJ Glob Health."},{"key":"ref-38","article-title":"Meeting Brief: stakeholder engagement to identify priority pathogens for serosurveillance in Kenya"},{"key":"ref-39","doi-asserted-by":"publisher","DOI":"10.1101\/2022.10.10.22280824","article-title":"SARS-CoV-2 seroprevalence and implications for population immunity: evidence from two Health and Demographic Surveillance System sites in Kenya, February\u2013June 2022.","author":"E Kagucia","year":"2022","journal-title":"medRxiv."},{"key":"ref-40","article-title":"Issue Brief. High seroprevalence of antibodies against COVID-19 within the general population: evidence from Nairobi and Kilifi","year":"2022"},{"key":"ref-41","article-title":"AFRO seminar on COVID-19 sero-epidemiological studies (\"UNITY\" studies): 27 June 2022"},{"key":"ref-42","article-title":"AFRO seminar on COVID-19 sero-epidemiological studies (\"UNITY\" studies): 27 March 2023"},{"key":"ref-43","article-title":"Visualization of seroprevalence across the country"},{"key":"ref-44","article-title":"From emergency response to long-term COVID-19 disease management: sustaining gains made during the COVID-19 pandemic","year":"2023"}],"container-title":["Gates Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/gatesopenresearch.org\/articles\/8-60\/v2\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/gatesopenresearch.org\/articles\/8-60\/v2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/gatesopenresearch.org\/articles\/8-60\/v2\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T05:15:11Z","timestamp":1749446111000},"score":1,"resource":{"primary":{"URL":"https:\/\/gatesopenresearch.org\/articles\/8-60\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":44,"URL":"https:\/\/doi.org\/10.12688\/gatesopenres.15569.2","relation":{"has-version":[{"id-type":"doi","id":"10.12688\/gatesopenres.15569.1","asserted-by":"subject"}],"has-review":[{"id-type":"doi","id":"10.21956\/gatesopenres.17710.r39475","asserted-by":"subject"},{"id-type":"doi","id":"10.21956\/gatesopenres.17710.r39640","asserted-by":"object"},{"id-type":"doi","id":"10.21956\/gatesopenres.17710.r39475","asserted-by":"object"}]},"ISSN":["2572-4754"],"issn-type":[{"value":"2572-4754","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"Indexed","URL":"https:\/\/gatesopenresearch.org\/articles\/8-60\/v2#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.21956\/gatesopenres.16925.r38034, Moses Masika, University of Nairobi, Nairobi, Nairobi County, 14 Oct 2024, version 1, 1 approved","URL":"https:\/\/gatesopenresearch.org\/articles\/8-60\/v1#referee-response-38034","order":0,"name":"referee-response-38034","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Shirine Voller<\/b>; \n<i>Posted: 14 Feb 2025<\/i>; Many thanks to Dr. Masika for the comments.&nbsp; We agree that the text describing the MAGPIX assay should be amended to &quot;multiplex bead-based fluorescence immuno-assay&quot;.  We have developed a schematic to provide a visual depiction of the project governance and management structures and would be happy for this to be added to the paper.&nbsp;","URL":"https:\/\/gatesopenresearch.org\/articles\/8-60\/v2#referee-comment-3766","order":1,"name":"referee-comment-3766","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.21956\/gatesopenres.17710.r39475, Mairead G Whelan, University of Calgary, Calgary, 09 Jun 2025, version 2, indexed","URL":"https:\/\/gatesopenresearch.org\/articles\/8-60\/v2#referee-response-39475","order":2,"name":"referee-response-39475","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"Bill & Melinda Gates Foundation (INV-039626) and Wellcome Trust (Grants 220991\/Z\/20\/Z and 203077\/Z\/16\/Z). The PBIDS sites are funded by US CDC through a Cooperative Agreement to Washington State University Global Health Kenya #6U01GH002143. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}